These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38594748)

  • 21. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
    Che XH; Chen CL; Ye XL; Weng GB; Guo XZ; Yu WY; Tao J; Chen YC; Chen X
    Oncol Rep; 2016 Mar; 35(3):1680-8. PubMed ID: 26707712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness.
    Hirano T; Satow R; Kato A; Tamura M; Murayama Y; Saya H; Kojima H; Nagano T; Okabe T; Fukami K
    Biochem Pharmacol; 2013 Nov; 86(10):1419-29. PubMed ID: 24035834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis.
    Yue B; Qiu S; Zhao S; Liu C; Zhang D; Yu F; Peng Z; Yan D
    J Gastroenterol Hepatol; 2016 Mar; 31(3):595-603. PubMed ID: 26487301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
    Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
    J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
    Tarantelli C; Cannas E; Ekeh H; Moscatello C; Gaudio E; Cascione L; Napoli S; Rech C; Testa A; Maniaci C; Rinaldi A; Zucca E; Stathis A; Ciulli A; Bertoni F
    Explor Target Antitumor Ther; 2021; 2(6):586-601. PubMed ID: 36046113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
    Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
    Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
    Dessein AF; Stechly L; Jonckheere N; Dumont P; Monté D; Leteurtre E; Truant S; Pruvot FR; Figeac M; Hebbar M; Lecellier CH; Lesuffleur T; Dessein R; Grard G; Dejonghe MJ; de Launoit Y; Furuichi Y; Prévost G; Porchet N; Gespach C; Huet G
    Cancer Res; 2010 Jun; 70(11):4644-54. PubMed ID: 20460542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exosomal lncRNA PVT1/VEGFA Axis Promotes Colon Cancer Metastasis and Stemness by Downregulation of Tumor Suppressor miR-152-3p.
    Lai SW; Chen MY; Bamodu OA; Hsieh MS; Huang TY; Yeh CT; Lee WH; Cherng YG
    Oxid Med Cell Longev; 2021; 2021():9959807. PubMed ID: 34336125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Proteomics Analysis Identifies Cdc42-Cdc42BPA Signaling as Prognostic Biomarker and Therapeutic Target for Colon Cancer Invasion.
    Hu HF; Xu WW; Wang Y; Zheng CC; Zhang WX; Li B; He QY
    J Proteome Res; 2018 Jan; 17(1):265-275. PubMed ID: 29072916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
    Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
    J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression.
    Yuan T; Ni P; Zhang Z; Wu D; Sun G; Zhang H; Chen B; Wang X; Cheng Z
    Cell Biol Int; 2023 Mar; 47(3):622-633. PubMed ID: 36448366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion.
    Lotz M; Wang HH; Cance W; Matthews J; Pories S
    J Surg Res; 2003 Feb; 109(2):123-9. PubMed ID: 12643853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.